Biocon Bets Big on Insulin, Eyes GLP-1 Drugs for Future Growth
Bengaluru – Biocon Biologics, the biopharmaceutical arm of Biocon Ltd, is strengthening its foothold in the global insulin market while making a decisive move into the booming GLP-1 drug segment.…







